Seres Therapeutics (MCRB) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- S&P 500 futures steady after midterm rally; Nasdaq lags on chip weakness
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MCRB Hot Sheet
Join SI Premium – FREE
Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.57), $0.02 worse than the analyst estimate of ($0.55).
For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evolent Health (EVH) Reports In-Line Q3 EPS ; Offers Guidance
- Global Payments (GPN) Reports In-Line Q3 EPS, Offers FY26 EPS Guidance
- Commerce.com, Inc. (CMRC) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
